ImmunityBio Shares Surge on European Regulatory Milestone

ImmunityBio's stock price experienced a dramatic single-day rally, closing with gains exceeding 33 percent. This surge in investor sentiment was triggered by a pivotal regulatory announcement from Europe, granting market access for the company's flagship oncology therapy.

The catalyst for the market movement was the European Commission's decision to issue a conditional marketing authorization for ANKTIVA (also known as nogapendekin alfa inbakicept). The therapy, used in combination with BCG, is approved for treating adult patients with non-muscle-invasive bladder cancer (NMIBC) who are unresponsive to prior BCG therapy. This authorization makes the treatment available across all 27 European Union member states, as well as in Iceland, Norway, and Liechtenstein.

Regulatory approval was based on compelling clinical evidence. Trial data demonstrated a complete response rate of 71 percent in the studied patient population. A significant quality-of-life benefit was also observed: more than 80 percent of treated patients retained their bladder over a three-year follow-up period. For many individuals with this condition, radical cystectomy (surgical removal of the bladder) had previously been the sole remaining option.

Financial Implications and Global Commercial Footprint

This European endorsement significantly expands ImmunityBio's commercial landscape to 33 countries worldwide. The company has achieved this global reach in under two years since ANKTIVA first received U.S. Food and Drug Administration (FDA) approval in April 2024. The drug is now commercially available in the United States, the United Kingdom, Saudi Arabia, and the European bloc.

Should investors sell immediately? Or is it worth buying ImmunityBio?

The financial impact of this market expansion is substantial. For the 2025 fiscal year, ImmunityBio has provided revenue guidance for ANKTIVA approximating $113 million. A strong indicator of accelerating commercial adoption is the therapy's 20 percent quarter-over-quarter growth recorded in the final quarter of 2025. The addressable patient population in Europe is considerable, with over 150,000 new diagnoses of this specific cancer type each year.

Clinical Development Pipeline and Forward Outlook

Looking beyond the initial indication, ImmunityBio is actively pursuing label expansions for ANKTIVA. Ongoing clinical investigations are evaluating its potential in treating solid tumors, ovarian cancer, and Lynch syndrome. Furthermore, the company initiated a Phase 2 clinical trial for lymphoma treatment in early February 2026.

It is important to note that the European authorization is conditional. As a result, ImmunityBio is obligated to submit ongoing long-term study data to regulators annually to confirm the therapy's continued safety and efficacy profile. Successful fulfillment of these requirements paves the way for the treatment's establishment as a standard of care in Europe, which would significantly broaden the company's revenue base in the coming years.